Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Common Stock")
-
Shares outstanding
-
244,800,444
-
Total 13F shares
-
164,371,652
-
Share change
-
-1,761,792
-
Total reported value
-
$460,365,265
-
Put/Call ratio
-
191%
-
Price per share
-
$2.80
-
Number of holders
-
152
-
Value change
-
-$1,917,859
-
Number of buys
-
66
-
Number of sells
-
72
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Common Stock") (ALLO) as of Q3 2024
As of 30 Sep 2024,
Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Common Stock") (ALLO) was held by
152 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
164,371,652 shares.
The largest 10 holders included
FMR LLC, TPG GP A, LLC, BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, Capital World Investors, Lynx1 Capital Management LP, PRIMECAP MANAGEMENT CO/CA/, CITADEL ADVISORS LLC, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
152
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.